Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Smoking Cessation 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hepatitis B 1Hematuria 1Fatigue 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Oxaliplatin 295Capecitabine 209Fluorouracil 183Cisplatin 172Docetaxel 140S 1 (combination) 135Paclitaxel 128Leucovorin 117Irinotecan 110pembrolizumab 104Trastuzumab 76Nivolumab 59apatinib 57Drug Therapy 52sintilimab 46Surgical Procedures, Operative 45Ramucirumab 40Radiotherapy 40Bevacizumab 37Hyperthermic Intraperitoneal Chemotherapy 34Epirubicin 32titanium silicide 31tislelizumab 31Carboplatin 31Gastrectomy 28Cyclophosphamide 27XELOX 25Tegafur 24Folfox protocol 23Albumin-Bound Paclitaxel 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Urinalysis × Clear all
NCT00580281 2013-10-24

Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors

Memorial Sloan Kettering Cancer Center

Phase NA Completed
33 enrolled
GastrointestinalMyeloidOther hematologic neoplasm

Leukemia, Stomach Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡